Androgen deprivation therapy affects BCL-2 expression in human prostate cancer

International Journal of Oncology

Volumn 39, Issue 5, 2011, Pages 1233-1242

  Fuzio, Paolo ^a   Ditonno, Pasquale ^b   Lucarelli, Giuseppe ^b   Battaglia, Michele ^b   Bettocchi, Carlo ^b   Senia, Trabucco ^b   Perlino, Elda ^a  

^a CNR   (Italy)

^b UNIVERSITY OF BARI   (Italy)

Author keywords

Androgen deprivation therapy; BCL 2; Expression regulation; Prostate cancer

Indexed keywords

BICALUTAMIDE; GOSERELIN; MESSENGER RNA; PROTEIN BCL 2;

ADJUVANT THERAPY; ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; GENETIC TRANSCRIPTION; HORMONAL REGULATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MALE; NORTHERN BLOTTING; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; UPREGULATION; WESTERN BLOTTING;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; CELL LINE, TUMOR; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, MESSENGER; TIME FACTORS; TRANSCRIPTION, GENETIC;

EID: 80053201752     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1140     Document Type: Article

References (30)

1. Akao Y, Otsuki Y, Kataoka S, Ito Y and Tsujimoto Y: Multiple subcellular localization of BCL-2: detection in nuclear outer membrane, endoplasmic reticulum membrane, and mitochondrial membranes. Cancer Res 54: 2468-2471, 1994. (Pubitemid 24138742)
2. Fulda S, Gorman AM, Hori O and Samali A: Cellular stress responses: cell survival and cell death. Int J Cell Biol 2010: 1-23, 2010.
3. Danial NN: BCL-2 family proteins: critical checkpoints of apoptotic cell death. Clin Cancer Res 13: 7254-7263, 2007.
4. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LW, Hsieh JT, et al: Expression of the protooncogene BCL-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 52: 6940-6944, 1992. (Pubitemid 23006303)
5. Colombel M, Symmans F, Gil S, O'Toole KM, Chopin D, Benson M, et al: Detection of the apoptosis-suppressing oncoprotein BCL-2 in hormone-refractory human prostate cancers. Am J Pathol 143: 390-400, 1993. (Pubitemid 24058194)
6. Krajewska M, Krajewski S, Epstein JI, Shabaik A, Sauvageot J, Song K, et al: Immunohistochemical analysis of BCL-2, bax, BCL-x and mcl-1 expression in prostate cancers. Am J Pathol 148: 1567-1576, 1996. (Pubitemid 26135897)
7. McConkey DJ, Greene G and Pettaway CA: Apoptosis resistance increase with metastatic potential in cells of the human LNCaP prostate carcinoma line. Cancer Res 56: 5594-5599, 1996. (Pubitemid 26422158)
8. Lu S, Tsai SY and Tsai MJ: Molecular mechanisms of androgen-independent growth of human prostate cancer LNCaP-AI cells. Endocrinology 140: 5054-5059, 1999.
9. Feldman BJ and Feldman D: The development of androgen independent prostate cancer. Nat Rev Cancer 1: 34-45, 2001. (Pubitemid 33741879)
10. Raffo AJ, Perlman H, Chen MW, Day ML, Streitman JS and Buttyan R: Overexpression of BCL-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res 55: 4438-4445, 1995.
11. Bruckheimer EM, Spurgers K, Weigel NL, Logothetis C and McDonnell TJ: Regulation of BCL-2 expression by dihydrotestosterone (DHT) in hormone sensitive LNCaP-FGC prostate cancer cells. J Urol 169: 1553-1557, 2003. (Pubitemid 36323842)
12. Yamanaka K, Rocchi P, Miyake H, Fazli L, Vessella B, Zangemeister-Wittke U, et al: A novel antisense oligonucleotide inhibiting several antiapoptotic BCL-2 family members induces apoptosis and enhances chemosensitivity in androgen-independent human prostate cancer PC3 cells. Mol Cancer Ther 4: 1689-1698, 2005. (Pubitemid 41685303)
13. Yamanaka K, Rocchi P, Miyake H, Fazli L, So A, Zangemeister-Wittke U, et al: Induction of apoptosis and enhancement of chemosensitivity in human prostate cancer LNCaP cells using bispecific antisense oligonucleotide targeting BCL-2 and BCL-xL genes. BJU International 97: 1300-1308, 2006. (Pubitemid 43907340)
14. Haldar S, Jena N and Croce CM: Inactivation of BCL-2 by phosphorylation. Proc Natl Acad Sci USA 92: 4507-4511, 1995.
15. Yoshino T, Shiina H, Urakami S, Kikuno N, Yoneda T, Shigeno K, et al: BCL-2 expression as a predictive marker of hormone-refractory prostate cancer treated with taxane-based chemotherapy. Clin Cancer Res 12: 6116-6124, 2006. (Pubitemid 44703777)
16. Gleave ME, Miayake H, Goldie J, Nelson C and Tolcher A: Targeting BCL-2 gene to delay androgen-independent progression and enhance chemosensitivity in prostate cancer using antisense BCL-2 oligodeoxynucleotides. Urology 54: 36-46, 1999.
17. Miayake H, Tolcher A and Gleave ME: Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense BCL-2 oligodeoxynucleotides. J Natl Cancer Inst 92: 34-41, 2000. (Pubitemid 30082226)
18. Pollack A, Cowen D, Troncoso P, Zagars GK, Von Eschenbach AC, Meistrich ML, et al: Molecular markers of outcome after radiotherapy in patients with prostate carcinoma. Cancer 97: 1630-1638, 2003. (Pubitemid 36350706)
19. Gleason DF: Histologic grading of prostate cancer: a perspective. Hum Pathol 23: 273-279, 1992.
20. Perlino E, Lovecchio M, Vacca RA, Fornaro M, Moro L, Ditonno P, et al: Regulation of mRNA and protein levels of beta1 integrin variants in human prostate carcinoma. Am J Pathol 157: 1727-1734, 2000.
21. Fuzio P, Lucarelli G, Perlino E, Battaglia M, Bettocchi C, Selvaggi FP, et al: Androgen deprivation therapy regulation of beta1C integrin expression in prostate cancer. Oncol Rep 22: 327-335, 2009.
22. Bhatia P, Taylor WR, Greenberg AH and Wright JA: Comparison of glyceraldehyde-3-phosphate dehydrogenase and 28S-ribosomal RNA gene expression as RNA loading controls for Northern blot analysis of cell lines of varying malignant potential. Anal Biochem 216: 223-226, 1994. (Pubitemid 24036854)
23. Rothermund CA, Kondrikov D, Lin MF and Vishwanatha JK: Regulation of Bcl-2 during androgen-unresponsive progression of prostate cancer. Prostate Cancer Prostatic Dis 5: 236-245, 2002.
24. Szostak MJ, Kaur P, Amin P, Jacobs SC and Kyprianou N: Apoptosis and bcl-2 expression in prostate cancer: significance in clinical outcome after brachytherapy. J Urol 165: 2126-2130, 2001.
25. Ohigashi T, Ueno M, Nonaka S, Nakanoma T, Furukawa Y, Deguchi N, et al: Tyrosine kinase inhibitors reduce bcl-2 expression and induce apoptosis in androgen-dependent cells. Am J Physiol Cell Physiol 278: C66-C72, 2000. (Pubitemid 30101896)
26. Rosser CJ, Reyes AO, Vakar-Lopez F, Levy LB, Kuban DA, Hoover DC, et al: Bcl-2 is significantly overexpressed in localized radio-recurrent prostate carcinoma, compared with localized radio-naive prostate carcinoma. Int J Radiat Oncol Biol Phys 56: 1-6, 2003. (Pubitemid 36403670)
27. Wu TT, Hsu YS, Wang JS, Lee YH and Huang JK: The role of p53, bcl-2 and E-cadherin expression in predicting biochemical relapse for organ confined prostate cancer in Taiwan. J Urol 170: 78-81, 2003. (Pubitemid 36734416)
28. Herzig MC, Trevino AV, Liang H, Salinas R, Waters SJ, MacDonald JR, et al: Apoptosis induction by the dual-action DNA- and protein-reactive antitumor drug irofulven is largely Bcl-2-independent. Biochem Pharmacol 65: 503-513, 2003. (Pubitemid 36144235)
29. Huang JM, Lin TY, Chang D, Lin SL and Ying SY: Truncated Bcl-2, a potential pre-metastatic marker in prostate cancer. Biochem Biophys Res Commun 306: 912-917, 2003. (Pubitemid 36776216)
30. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, et al: Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91: 231-241, 1997. (Pubitemid 27456390)